Clinical Trial Results:
            Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age                                                                                                                                 
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2007-000420-40 | 
    Trial protocol  | 
        FI SE HU FR NL | 
    Global completion date  | 
        
                                    07 Jun 2013
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    12 Jul 2016
                             
         | 
    
    First version publication date  | 
        
                                    21 Dec 2014
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                Bayer Study Synopsis | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.